Preparation and Characterization of Silymarin-Conjugated Gold Nanoparticles with Enhanced Anti-Fibrotic Therapeutic Effects against Hepatic Fibrosis in Rats: Role of MicroRNAs as Molecular Targets

• Published in: Biomedicines Vol. 9; no. 12; p. 1767
• Main Authors: Abdullah, Abdullah Saad, El Sayed, Ibrahim El Tantawy, El-Torgoman, Abdel Moneim A, Alghamdi, Noweir Ahmad, Ullah, Sami, Wageh, S, Kamel, Maher A
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 25.11.2021; MDPI
• Subjects: Anesthesia; Antioxidants; Bioavailability; Biochemical analysis; Biocompatibility; Body weight; Carbon tetrachloride; epigenetics; Fibrosis; Gene expression; Gold; gold nanoparticles; Hepatitis; Immunohistochemistry; Inflammation; Lipid peroxidation; Liver diseases; liver fibrosis; MicroRNAs; miRNA; Nanoparticles; oxidative stress; Silymarin; Spain; microRNAs; liver fibrosis; silymarin; gold nanoparticles; epigenetics; oxidative stress
• ISSN: 2227-9059; 2227-9059
• DOI: 10.3390/biomedicines9121767

The main obstacles of silymarin (SIL) application in liver diseases are its low bioavailability, elevated metabolism, rapid excretion in bile and urine, and inefficient intestinal resorption. The study aimed to synthesize and characterize silymarin-conjugated gold nanoparticles (SGNPs) formulation to improve SIL bioavailability and release for potentiating its antifibrotic action. Both SGNPs and gold nanoparticles (GNPs) were prepared and characterized using standard characterization techniques. The improved formulation was assessed for in vitro drug release study and in vivo study on rats using CCl induced hepatic fibrosis model. SIL, SGNPs, and GNPs were administered by oral gavage daily for 30 days. At the end of the study, rats underwent anesthesia and were sacrificed, serum samples were collected for biochemical analysis. Liver tissues were collected to measure the genes and microRNAs (miRNAs) expressions. Also, histopathological and immunohistochemistry (IHC) examinations of hepatic tissues supported these results. The successful formation and conjugation of SGNPs were confirmed by measurements methods. The synthesized nanohybrid SGNPs showed significant antifibrotic therapeutic action against CCl -induced hepatic damage in rats, and preserved normal body weight, liver weight, liver index values, retained normal hepatic functions, lowered inflammatory markers, declined lipid peroxidation, and activated the antioxidant pathway nuclear factor erythroid-2-related factor 2 (NRF2). The antifibrotic activities of SGNPs mediated through enhancing the hepatic expression of the protective miRNAs; miR-22, miR-29c, and miR-219a which results in suppressed expression of the main fibrosis mediators; TGFβR1, COL3A1, and TGFβR2, respectively. The histopathology and IHC analysis confirmed the anti-fibrotic effects of SGNPs. The successful synthesis of SGNPs with sizes ranging from 16 up to 20 nm and entrapment efficiency and loading capacity 96% and 38.69%, respectively. In vivo studies revealed that the obtained nano-formulation of SIL boosted its anti-fibrotic effects.